Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.69 |
| ▸ | CA9 | Q16790 | 5/20 | 0.69 |
| ▸ | CA1 | P00915 | 3/20 | 0.69 |
| ▸ | CA2 | P00918 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | IL2 | P60568 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.49 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.49 |
| ▸ | ALDH1B1 | P30837 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8634263 | 1.00 | CA12 (0.69) | CA12CA9CA1CA2KMT2A | |
| SCHEMBL382083 | 0.84 | CA12 (0.74) | CA12CA9CA1CA2KMT2A | |
| SCHEMBL6228083 | 0.84 | CA12 (0.74) | CA12CA9CA1CA2KMT2A | |
| SCHEMBL3366849 | 0.82 | CA12 (0.71) | CA12CA9CA1CA2KMT2A | |
| SCHEMBL3361018 | 0.82 | CA12 (0.70) | CA12CA9CA1CA2KMT2A | |
| SCHEMBL1526661 | 0.82 | CA12 (1.00) | CA12CA9CA1CA2KMT2A | |
| SCHEMBL755988 | 0.82 | CA12 (1.00) | CA12CA9CA1CA2KMT2A | |
| SCHEMBL2319034 | 0.82 | CA12 (1.00) | CA12CA9CA1CA2KMT2A | |
| SCHEMBL10048269 | 0.82 | CA12 (1.00) | CA12CA9CA1CA2KMT2A | |
| SCHEMBL15745917 | 0.82 | CA12 (1.00) | CA12CA9CA1CA2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3284469-B1 | COMPOSITIONS AND METHODS FOR DETECTION OF LYSOSOMAL STORAGE DISEASE | GENZYME CORP (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-3284469-A2 | COMPOSITIONS AND METHODS FOR DETECTION OF LYSOSOMAL STORAGE DISEASE | Genzyme Corporation (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-2535050-B1 | Compositions and methods for detection of lysosomal storage disease | GENZYME CORP (US) | 2017-07-05 | — | — | EP | disclosed |
| EP-2139323-B1 | TREATMENT OF GAUCHER DISEASE WITH SPECIFIC PHARMACOLOGICAL CHAPERONES AND MONITORING TREATMENT USING SURROGATE MARKERS | AMICUS THERAPEUTICS INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8431335-B2 | Glucosyl ceramide, sodium taurocholate, and buffer; bioassays | GENZYME CORPORATION (US) | 2013-04-30 | — | — | US | disclosed |
| US-8399525-B2 | Treatment of gaucher disease with specific pharmacological chaperones and monitoring treatment using surrogate markers | AMICUS THERAPEUTICS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| EP-2535050-A2 | Compositions and methods for detection of lysosomal storage disease | GENZYME CORPORATION (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20100196279-A1 | TREATMENT OF GAUCHER DISEASE WITH SPECIFIC PHARMACOLOGICAL CHAPERONES AND MONITORING TREATMENT USING SURROGATE MARKERS | AMICUS THERAPEUTICS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| EP-2139323-A1 | TREATMENT OF GAUCHER DISEASE WITH SPECIFIC PHARMACOLOGICAL CHAPERONES AND MONITORING TREATMENT USING SURROGATE MARKERS | Amicus Therapeutics, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-2061477-A2 | COMPOSITIONS AND METHODS FOR DETECTION OF LYSOSOMAL STORAGE DISEASE | Genzyme Corporation (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008128106-A1 | TREATMENT OF GAUCHER DISEASE WITH SPECIFIC PHARMACOLOGICAL CHAPERONES AND MONITORING TREATMENT USING SURROGATE MARKERS | AMICUS THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080248512-A1 | Methods for detection of lysosomal storage disease | GENZYME CORPORATION (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080248513-A1 | Methods for detection of lysosomal storage disease | GENZYME CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080145836-A1 | Compositions and methods for detection of lysosomal storage disease | GENZYME CORPORATION (US) | 2008-06-19 | — | — | US | disclosed |
| WO-2008033427-A2 | COMPOSITIONS AND METHODS FOR DETECTION OF LYSOSOMAL STORAGE DISEASE | GENZYME CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196279-A1 | TREATMENT OF GAUCHER DISEASE WITH SPECIFIC PHARMACOLOGICAL CHAPERONES AND MONITORING TREATMENT USING SURROGATE MARKERS | GBA1, GAA, GBA3 | CA12 3119/4885CA9 3670/4885CA1 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.